BerGenBio (BGBIO) has announced the appointment of a new chief executive officer (CEO), Martin Olin, with effect from 8 September 2021. Martin Olin has more than two decades of executive experience in the pharmaceutical and biotechnology industry and previously served as CEO of Symphogen, a clinical-stage biotech developing monoclonal antibody based treatments for a variety of cancers, prior to its acquisition by Servier in 2020. While the timing of this announcement does come as a surprise, we ....
24 Aug 2021
BerGenBio - Martin Olin succeeds Richard Godfrey as CEO
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
BerGenBio - Martin Olin succeeds Richard Godfrey as CEO
- Published:
24 Aug 2021 -
Author:
John Priestner -
Pages:
2
BerGenBio (BGBIO) has announced the appointment of a new chief executive officer (CEO), Martin Olin, with effect from 8 September 2021. Martin Olin has more than two decades of executive experience in the pharmaceutical and biotechnology industry and previously served as CEO of Symphogen, a clinical-stage biotech developing monoclonal antibody based treatments for a variety of cancers, prior to its acquisition by Servier in 2020. While the timing of this announcement does come as a surprise, we ....